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Pathogenic Epitopes of Autoantibodies in Pemphigus
Reside in the Amino-Terminal Adhesive Region of
Desmogleins Which Are Unmasked by Proteolytic
Processing of Prosequence
Mariko Yokouchi1, Marwah Adly Saleh1, Keiko Kuroda2, Takahisa Hachiya2, John R. Stanley3,
Masayuki Amagai1 and Ken Ishii1
Pemphigus targets desmogleins (Dsgs), which are thought to be synthesized as inactive precursor proteins with
prosequences that are cleaved by substilisin-like proprotein convertases, such as furin, to yield mature adhesive
molecules. We hypothesized that some pemphigus pathogenic antibodies (Abs), which presumably interfere
with adhesion, only bind the mature form. A pathogenic and three non-pathogenic anti-Dsg1 monoclonal Abs
(mAbs) isolated from a pemphigus foliaceus (PF) patient, were used for immunoprecipitation and ELISA of
recombinant precursor and mature Dsg1. The pathogenic Ab binds mature Dsg1, whereas non-pathogenic Abs
bind either only the precursor or both the precursor and mature Dsg1. Competition ELISA showed that the
majority of PF sera target the same or nearby epitopes defined by the pathogenic anti-Dsg1 mAb that blocked
420% binding of 29 out of 40 PF sera. Furthermore, the immunoreactivity of 45 PF sera against the mature Dsg1
was 3.2 fold stronger than that against the precursor Dsg1 by ELISA. Similar results were observed in anti-Dsg3
Abs in 47 pemphigus vulgaris sera, suggesting that most pemphigus sera target epitopes that are unmasked by
proteolytic processing. These findings support the idea that at least some pathogenic pemphigus
autoantibodies induce the loss of cell adhesion by directly binding the trans-interaction site of Dsgs.
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INTRODUCTION
Pemphigus is a tissue-specific autoimmune disease charac-
terized by the loss of intercellular adhesion of keratinocytes
because of the binding of autoantibodies to the cell surface
(Stanley and Amagai, 2006). Pemphigus consists of two major
subtypes, pemphigus foliaceus (PF) and pemphigus vulgaris
(PV), in which autoantibodies target cadherin-type cell
adhesion molecules, desmoglein 1 (Dsg1) and Dsg3, res-
pectively. The autoantibodies are thought to block the cell
adhesive function mediated by Dsgs, inducing blister forma-
tion in the skin and mucous membranes.
The mechanism by which anti-Dsg autoantibodies induce
the loss of keratinocyte cell adhesion is still a matter of
discussion. One explanation is that of steric hindrance, in
which pathogenic autoantibodies induce the loss of cell
adhesion by directly interfering with the trans-interaction of
Dsg. Another explanation is that the blister formation requires
cellular responses, including internalization and degradation
of Dsg, and intercellular signaling, such as p38MAPK, Rho
family GTPase, c-myc, protein kinase C, and phospholipase
C (Esaki et al., 1995; Berkowitz et al., 2005; Calkins et al.,
2006; Waschke et al., 2006; Williamson et al., 2006)(review
in (Sharma et al., 2007).
Although it was shown that anti-Dsg antibodies (Abs) are
involved in blister formation in pemphigus, not all anti-Dsg
Abs are pathogenic. Recent studies using monoclonal Abs
(mAbs) from pemphigus mice model or from pemphigus
patients’ lymphocytes by phage display showed that there are
both pathogenic and non-pathogenic Abs (Tsunoda et al.,
2003; Payne et al., 2005; Ishii et al., 2008). For example, we
recently isolated a cohort of human anti-Dsg1 mAbs as
single-chain variable fragments (scFv) from a PF patient using
phage display (Ishii et al., 2008). Out of 67 unique mAbs
isolated, only two anti-Dsg1 mAbs showed pathogenic
activity, as they induced blister formation in mouse and/or
human skin, thereby indicating that anti-Dsg Abs consist
of pathogenic and non-pathogenic Abs. Determining factors
for influencing Abs’ pathogenicity may be important for
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developing disease-specific therapy or correct evaluation for
disease activity. Epitopes seem to be an important factor for
pathogenicity. The pathogenic Abs tend to bind the amino-
terminal extracellular domain of Dsgs that is predicted to
form the trans-adhesive interface between cells, whereas the
non-pathogenic Abs bind more membrane-proximal extra-
cellular domains.
Cadherins, including Dsgs, are thought to be initially
synthesized as inactive precursor proteins in the endoplasmic
reticulum, and transit through the cis-and trans-Golgi (Ozawa
and Kemler, 1990). Subsequently, they are processed by
subtilisin-like proprotein convertases, such as furin, to
become biologically active mature proteins, and assembled
into adherence junctions or desmosomes (Posthaus et al.,
1998; Wahl et al., 2003) (Figure 9a). The proteolytic cleavage
sites are well conserved among cadherins, although the size
of the prosequences is different between classic cadherins
and Dsgs, that is, B130 amino acids and B25 amino acids,
respectively (Koch et al., 2004). Previous studies on
E-cadherin showed that, if this proteolytic cleavage is
impaired, proE-cadherin integrates into the membrane but
is not able to confer adhesiveness, as the prosequence may
prevent successful interaction either by steric hindrance or by
masking a recognition site (Ozawa and Kemler, 1990).
Recent studies using nuclear magnetic resonance revealed
that the prosequence of N-cadherin is a folded domain that
may prevent the homophilic trans-interactions between the
molecules (Koch et al., 2004).
In this study, we focused on the effect of proteolytic
processing on the binding of autoantibodies against Dsgs. We
took advantage of the availability of pathogenic and non-
pathogenic mAbs. We hypothesized that pathogenic Abs
bind the epitopes that are masked by the prosequence and
unmasked by proteolytic processing, if pathogenic autoanti-
bodies induce the loss of cell adhesion by directly interfering
with the trans-interaction of Dsg. We found that a pathogenic
Ab recognized the epitope on Dsg1 that was unmasked by
proteolytic processing. Furthermore, the majority of anti-Dsg
Abs binding in PV and foliaceus patients target the mature
form compared with the precursor form of Dsg. This finding is
consistent with the pathogenic Abs binding to adhesive sites
on Dsgs, perhaps directly interfering with their function.
RESULTS
Proteolytic cleavage of Dsg1 increases binding of a pathogenic
PF scFv on ELISA assay
We previously reported the cloning of anti-Dsg1 mAbs from a
PF patient (Ishii et al., 2008). Genetic analysis of the PF mAb
library showed 67 unique mAbs based on V(D)J gene usage,
heavy- and light-chain combinations, and somatic hypermu-
tation. These mAbs were encoded by a total
of 12 variable VDJ genes, and also by a total of only five
variable heavy-chain (VH) genes. Predictably, all clones
were bound to Dsg1, as shown by immunoprecipitation.
But intriguingly, some clones immunoprecipitatied a bacu-
lovirus-produced recombinant Dsg1 protein with a slightly
greater apparent molecular weight on SDS-PAGE than other
clones (Ishii et al., 2008). In addition, the Abs that bound
only the higher molecular weight Dsg1 polypeptide
(3-97/1c, 3-94/O18O8) showed intracellular staining in the
superficial layers of the epidermis using immunofluorescence
(See Ishii et al., 2008, and Figure 1). As the insect cells
transfected with recombinant baculovirus produce both a
precursor and a mature protein form of Dsg1 (Hanakawa
et al., 2002), and as the precursor form is believed to be
localized in the endoplasmic reticulum to early Golgi (Wahl
et al., 2003), we hypothesized that some mAbs bound the
precursor form of Dsg1.
To test the hypothesis, we used furin, a human subtilisin-
related proprotein convertase to cleave the precursor form of
Dsg1 to obtain a mature form. As previously mentioned,
baculovirally produced recombinant Dsg1 contains both
precursor form and mature form. To confirm whether furin
can cleave the precursor form of recombinant Dsg1 produced
by the baculovirus expression system, we directly added furin
to the culture supernatant of Dsg1-EHis baculoprotein. As
shown in Figure 2a, Dsg1-EHis was detected as double
bands, the higher and lower band were most likely the
precursor form and mature form, respectively. After furin
treatment, Dsg1-EHis was detected as a single band, the
molecular weight of which was the same as that of the lower
band, indicating that furin cleaved almost all precursor Dsg1-
EHis into the mature form. As ELISA plates with baculovirus-
produced Dsg1-EHis were expected to contain both mature
and precursor forms of Dsg1, we examined the change in
reactivity of mAbs against Dsg1 ELISA plates after treating
them with furin (Figure 2b). We chose one pathogenic (3-30/
3h) and three non-pathogenic PF mAbs (3-97/1c, 3-94/
O18O8, 1-18/L12) (detailed in Table 1) as representative
Abs. The reactivity of 1-18/L12, which recognizes a linear
epitope on the extracellular domain 3 (EC3) of Dsg1, did not
show any significant change. However, the reactivity of 3-97/1c
3-30/3h 1-18/L12
3-97/1c3-94/O18O8
Figure 1. Confocal microscopy of anti-desmoglein 1 single-chain variable
fragment (scFv) mAbs on human skin. 3-30/3h and 1-18/L12 scFv antibodies
stained the cell surface of keratinocytes throughout human epidermis. 3-97/1c
and 3-94/O18O8 showed cytoplasmic staining in the superficial layers of the
epidermis. Scale bars: 50mm.
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was decreased after treatment with furin, consistent with the
hypothesis that this Ab recognizes only the precursor form.
The reactivity of the pathogenic Ab, 3-30/3h, was signifi-
cantly increased after furin treatment, indicating that patho-
genic 3-30/3h bound to an epitope on Dsg1, which was more
accessible or increased in amount after furin treatment.
A pathogenic scFv recognizes the mature, but not precursor,
form of Dsg1
There may be limitations for furin pretreatment of the ELISA
plate coated with Dsg, because it may not lead to a complete
cleavage of Dsg1 proteins. Therefore, we further confirmed
the above observations by analyzing the immunoreactivity of
various anti-Dsg1 mAbs against both a precursor and a
mature form of a recombinant extracellular region of Dsg1
using immunoprecipitation. To obtain a precursor form of
Dsg1, we used a mutated recombinant Dsg1, named
precursor-FacX-Dsg1, in which the normal endoproteolytic
cleavage site of Dsg1 (R-Q-K-R) was replaced with the
recognition site (I-E-G-R) of serum coagulation factor Xa
(Figure 3a). Recombinant baculovirus containing the mutant
precursor-FacX-Dsg1 complementary DNA was infected into
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Figure 2. Binding capacity of anti-desmoglein 1 (Dsg1) single-chain variable
fragment (scFv) mAbs to the Dsg1 ELISA plate changes after furin treatment.
(a) Baculovirally produced recombinant Dsg1 (Dsg1-EHis), visualized by
immunoblot using anti-E-tag antibody. Dsg1-EHis was detected as double
bands, which were considered to be precursor and mature form of Dsg1-EHis
(left lane). After treatment with furin protease, only single band was observed
(right lane). White arrowhead indicates the precursor form and black
arrowhead indicates the mature form. (b) Comparison of anti-Dsg1 scFv mAbs
bindings between furin-treated and Tris-buffered saline-calcium (TBS-Ca)-
treated (control) Dsg1 ELISA plates. The ratio was calculated according to the
following formula: (optical density (OD) values obtained in furin-treated
wells)/(OD values obtained in TBS-Ca-treated wells). Control ratio (ratio¼ 1)
is shown by a broken line. The binding of 3-30/3h, a pathogenic mAb, was
significantly increased to nearly twofold, whereas that of 3-97/1c, non-
pathogenic mAb was decreased. The binding of 1-18/L12 showed no
significant change. AM3-13 is an irrelevant scFv and used as a control.
Table 1. Epitopes and pathogenicity of anti-Dsg1 mAbs
Name of clones Epitope type Deduced epitope
Pathogenic antibody 3-30/3h Conformational aa 89–101 of Dsg1
Non-pathogenic antibodies 3-97/1c Conformational Precursor form of Dsg1
3-94/O18O8 Conformational Precursor form of Dsg1
1-18/L12 Linear EC3 of Dsg1
Abbreviations: aa, amino acid; Dsg, desmoglein; EC, extracellular domain.
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Figure 3. Binding of anti-desmoglein 1 (Dsg1) single-chain variable fragment
(scFv) mAbs to precursor-FacX-Dsg1 and mature Dsg1. (a) Molecular
structure of precursor-FacX-Dsg1-EHis and mature-Dsg1-EHis. To obtain
precursor form, the recognition sequence in precursor Dsg1 was substituted
with that of blood coagulation factor Xa (R-Q-K-R-I-E-G-R) by endogenous
proprotein convertases. To obtain mature form of Dsg1, recombinant Dsg1-
EHis produced by baculovirus expression system was treated with proprotein
convertase furin. (b) Precursor-FacX-Dsg1-EHis and mature-Dsg1-EHis
recombinant baculoprotein were immunoprecipitated with representative
anti-Dsg1 scFv antibodies or control scFv (AM3-13) and detected on an
immunoblot by anti-E-tag antibody.
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High Five-cultured insect cells, and precursor-FacX-Dsg1 was
produced in culture supernatant without cleaving the
prosequence. To generate the mature form of Dsg1-EHis,
named mature-Dsg1-EHis, we incubated the Dsg1-EHis
baculoprotein with furin. As shown in Figure 3b, precursor-
FacX-Dsg1 and mature-Dsg1-EHis were produced as a single
band on immunoblots, and precursor-FacX-Dsg1 had a
slightly higher molecular weight than mature-Dsg1-EHis.
Precursor-FacX-Dsg1 and mature-Dsg1 were immunopreci-
pitated with representative anti-Dsg1 mAbs or a control mAb
(AM3-13) and detected on western blots by an anti-E-tag Ab.
The pathogenic mAb, 3-30/3h, immunoprecipitated only the
mature form of Dsg1. Non-pathogenic mAbs, 3-97/1c and
3-94/O18O8, immunoprecipitated only the precursor form of
Dsg1. Another non-pathogenic mAb, 1-18/L12, immunopreci-
pitated both the precursor and mature forms of Dsg1.
Taken together, these data show that a pathogenic anti-
Dsg1 mAb recognized the mature form, but not the precursor
form of Dsg1, whereas non-pathogenic mAb binds either only
the precursor form or both the precursor and mature Dsg1.
The majority of PF sera target the same or nearby epitopes
defined by a pathogenic anti-Dsg1 mAb
Next, we examined whether other PF sera target epitopes
defined by the isolated anti-Dsg1 mAbs. To do so,
we carried out competition ELISA to see the inhibition
of the binding against Dsg1 of 40 PF sera by adding the mAbs
(Figure 4). As competitors, we used the pathogenic mAb,
3-30/3h, and non-pathogenic mAbs, 3-97/1c, 3-94/O18O8,
and 1-18/L12. The strongly pathogenic mAb 3-30/3h blocked
420 % binding of 29 out of 40 PF sera (73%). Furthermore,
14 sera were blocked over 50% and seven sera were blocked
over 80%. In contrast, non-pathogenic Abs (3-97/1c, 3-94/
O18O8) that recognized precursor Dsg1, blocked 420%
binding against Dsg1 in 10 out of 40 (25%) PF patients’ sera.
Four sera were blocked over 50% binding by 3-97/1c and
3-94/O18O8. None of the 40 sera were blocked over 20% by
1-18/L12, which is a non-pathogenic Ab recognizing a linear
epitope of the middle portion of Dsg1.
These data indicate that the pathogenic mAb isolated from
one PF patient defines a major pathogenic epitope targeted
by most PF sera. On the other hand, the shared immunor-
eactivity among PF sera against non-pathogenic epitopes
defined by several scFv from this PF patient is less, although a
certain proportion of anti-Dsg1 reactivity in some PF sera
targets the precursor form.
Next, we determined the finer epitope mapping of the
pathogenic 3-30/3h using immunoprecipitation–immunoblot
assay using a series of six Dsg1/Dsg3 and five Dsg1/Dsg2
chimeric molecules ((Sekiguchi et al., 2001) and Chan
et al.(manuscript in preparation)). As shown in Figure 5,
immunoprecipitation analysis using a domain-swapped
molecule of Dsg1/Dsg2 or Dsg3 revealed that the epitope
of 3-30/3h was mapped to amino acid 89–101 of the EC1
region of Dsg1.
Immunoreactivity against Dsgs in the majority of pemphigus
sera is increased by proteolytic processing of precursor to
mature Dsg
As much of the immunoreactivity of PF sera targeted the same
or nearby epitopes defined by the pathogenic mAb 3-30/3h,
which recognized only the mature form of Dsg1, we
hypothesized that most autoantibodies in the PF sera target
the mature, compared with the precursor, form of Dsg1. To
verify this hypothesis, we generated ELISA plates coated with
highly purified mature or precursor Dsg1 to compare the
immunoreactivity of multiple pemphigus sera against a
precursor and a mature form of Dsg1.
To obtain purified precursor Dsg1, recombinant Dsg1-
EHis baculoprotein was passed through an immunoadsorption
column containing mAb 3-30/3h to eliminate mature Dsg1.
To achieve a purified mature form of Dsg1, recombinant
Dsg1-EHis baculoprotein treated with furin was passed
through an immunoadsorption column containing mAb
3-97/1c to remove the precursor form (Figure 6a). Those
purified recombinant baculoproteins were coated on ELISA
plates to generate purified mature Dsg1 and precursor Dsg1
ELISA plates. We confirmed that these ELISA plates contained
either mature or precursor forms by immunoreactivities of
anti-Dsg1 mAbs (Figure 6b). 3-30/3h reacted against the
complete-mature Dsg1 plate in a dose-dependent manner,
but did not react to the complete-precursor Dsg1. In contrast,
3-97/1c
3-30/3h
3-94/O18O8
1-18/L12
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Figure 4. Competition ELISA of PF sera binding by anti-desmoglein 1 (Dsg1) single-chain variable fragment (scFv) mAbs. Competition ELISA of 40 PF sera
was carried out to see if the binding against standard Dsg1 ELISA plates of PF sera was blocked by adding anti-Dsg1scFv mAbs. 3-30/3h (shown in
orange), 3-97/1c, 3-94/O18O8 (shown in green) and 1-18/L12 (shown in blue) were used as competitors. When420% inhibition was considered as significant
(shown in broken line), the bindings were blocked by pathogenic 3-30/3h mAb in 29 PF sera. 3-97/1c and 3-94/O18O8, which recognized the precursor
form, blocked the binding in 10 PF sera.
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3-97/1c showed dose-dependent reactivity to the complete-
precursor plate, but showed no reactivity to the complete-
mature plate. 1-18/L12 exhibited similar reactivity against
both plates.
We tested 45 PF sera and 20 mucocutaneous PV sera,
which contained an anti-Dsg1 Ab in addition to an anti-Dsg3
Ab. Strikingly, all PF sera, except two, showed stronger
reactivity against the mature Dsg1 plate than against the
precursor Dsg1 plate (Figure 6c). The average and standard
deviation of immunoreactivity, as determined by ELISA
optical density (OD), against mature Dsg1 was 1.37±0.32,
whereas the average and standard deviation of immunor-
eactivity against the precursor form was 0.43±0.23. Differ-
ence between immunoreactivity against mature and
precursor Dsg1 was statistically significant (paired t-test,
Po0.001). For PV sera that contained Dsg1 and Dsg3 Abs, all
sera but two also reacted more strongly to the mature Dsg1
ELISA plate than to the precursor ELISA plate (Figure 6d). The
average and standard deviation of the ELISA OD of PV sera
against mature Dsg1 was 1.26±0.41, whereas the average
and standard deviation against precursor Dsg1 was
0.31±0.16, which was a statistically significant difference
(Po0.001). These findings show that the majority of
pemphigus sera containing anti-Dsg1 Abs target epitopes
that are unmasked by proteolytic processing.
As changes in the reactivity of anti-Dsg3 mAbs have also
been observed on Dsg3 ELISA plates with different ratios of
precursor and mature Dsg3 (Sharma et al., 2009), we also
tested the well-characterized mouse anti-Dsg3 mAb AK series
and PV sera on ELISA plates with purified mature or precursor
Dsg3. To obtain precursor Dsg3, we used a mouse anti-Dsg3
mAb, AK23, obtained from PV model mice (Tsunoda et al.,
2003). AK23, a pathogenic anti-Dsg3 mouse monoclonal Ab,
targets an epitope on the adhesive interface of Dsg3
molecules and binds only to the mature form (Tsunoda
et al., 2003). Recombinant Dsg3-EHis baculoprotein was
passed through an immunoadsorption column containing
AK23 mAb to eliminate mature Dsg3. To obtain mature Dsg3,
recombinant Dsg3-EHis baculoprotein was treated with furin
(Figure 7a). We confirmed the accuracy of ELISA plates
coated with the purified mature and precursor Dsg3 by
mouse anti-Dsg3 mAbs, AK23, and AK15 (Figure 7b). AK15 is
an anti-Dsg3 monoclonal Ab that recognizes a linear epitope
in the middle portion of Dsg3, so that the Ab should bind
both the mature and precursor forms of Dsg3. AK23 mAb
showed dose-dependent reactivity to the complete-mature
plate, while showing no reactivity to the complete-precursor
plate. AK15 mAb exhibited similar binding capacity to both
plates.
We tested 47 PV sera against these plates. All but five PV
sera had stronger reactivity against the complete-mature plate
than against the complete-precursor plate (Figure 7c). For PV
sera, the average and standard deviation of immunoreactivity
against mature Dsg3 was 0.74±0.36, whereas the average
and standard deviation of immunoreactivity against the
precursor form was 0.20±0.13 (paired t-test, Po0.001).
These data suggest that the majority of anti-Dsg3 immunor-
eactivity in PV also targets epitopes that are unmasked by
proteolytic processing.
Titers measured by mature Dsg ELISA tend to reflect the disease
activity more precisely than that by the precursor Dsg ELISA
Finally, we analyzed PF and PV cases for immunoreactivity
against the mature and precursor forms of Dsg1 and Dsg3
over time, and compared them with clinical disease activity.
First, we analyzed three PF and three PV cases in which the
immunoreactivity against the mature form was stronger than
that against the precursor form of Dsg because we considered
them as typical cases. As shown in Figure 8a–f, the
immunoreactivity against both the mature and precursor
Dsg tended to fluctuate in parallel with disease activity.
However, immunoreactivity against the mature form was a
more sensitive indicator of disease activity in most patients,
because the reactivity against the precursor was often
minimal or negative, even at times of disease activity (Figure
8a–d and f). We also analyzed two unusual cases that showed
stronger reactivity against the precursor Dsg plate than
against the mature form (Figure 8g and h). In one case
(Figure 8g), the ELISA reactivity against the precursor Dsg did
reflect the disease activity well, but in the other (Figure 8h),
EC1
Dsg1
Dsg2
Dsg3
Dsg11-87/Dsg387-566
Dsg11-64/Dsg365-566
Dsg11-24/Dsg325-566
Dsg31-26/Dsg126-496
Dsg31-63/Dsg163-496
Dsg31-88/Dsg189-496
Dsg1EC1-Dsg2
Dsg1EC2-Dsg2
Dsg1EC3-Dsg2
Dsg1EC4-Dsg2
Dsg1EC5-Dsg2
EC2 EC3 EC4 EC5
+
−
−
−
−
−
+
+
+
+
496
566
566
1
1
1
1
1
1
1
1
1
87
87
65
64
25
24
26
26
63
63
88
89
101
566
566
496
496
496
89
101
Deduced epitope: ~
−
−
−
−
3-3
0/3
h
Figure 5. Epitope mapping of pathogenic 3-30/3h mAb. Wild-type and
domain-swapped extracellular domains of human desmoglein 1 (Dsg1) and
Dsg3, and of Dsg1 and Dsg2 produced by baculovirus expression system
were used for immunoprecipitation with 3-30/3h mAb. The molecular
structure of domain-swapped molecules is shown. The results of
immunoprecipitation assays with 3-30/3h mAb are listed in the right panel.
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the reactivity against the precursor did not fall with decreased
disease activity, as did the reactivity against the mature
protein. In summary, considering all the patients whom we
tested (Figure 8), reactivity against the mature protein
correlated well with disease activity, whereas reactivity
against the precursor Dsg sometimes did not.
DISCUSSION
Detailed characterization of monoclonal anti-Dsg1 Abs
isolated from a PF patient revealed that the patient had Abs
against the mature and precursor forms of Dsg1. We also
found that a pathogenic Dsg1 Ab binds only the mature form,
whereas non-pathogenic ones bind only the precursor form
or bind both mature and precursor forms. These findings led
us to explore the immunoreactivity of multiple pemphigus
sera against the mature and precursor forms of Dsg1 and 3.
Competition ELISA showed that much of the immunoreactiv-
ity in multiple PF sera binds to the same, or nearby, epitopes
defined by the pathogenic Ab. ELISA using the mature and
precursor Dsgs showed that much of the immunoreactivity in
the majority of pemphigus sera target the mature form of Dsg
than with the precursor form. Furthermore, a longitudinal
study of pemphigus patients showed that immunoreactivity
against the mature Dsg reflects the disease activity well. All
these findings suggest that epitopes that are masked by the
prosequence are very important in pathogenesis in pemphigus.
Although the pathogenic PF monoclonal anti-Dsg1 Ab,
used in this study, which binds only the mature form of Dsg1,
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Figure 6. Majority of anti-desmoglein 1 (Dsg1) antibody binding in PF and PV sera targets the mature form more than the precursor form of Dsg1. (a)
Coomassie blue staining of purified recombinant baculoproteins used for precursor and mature Dsg1 ELISA plates. White arrowhead indicates the precursor form
and black arrowhead indicates the mature form. (b) Binding curves of representative anti-Dsg1 scFv antibodies (3-30/3h, 3-97/1c, 1-18/L12) and control scFv
(AM3-13) against mature and precursor Dsg1 ELISA plate. (c) Dispersion of immunoreactivity of 45 PF sera between the mature and precursor Dsg1 ELISA plate.
Each closed square represents single patient. Note that most PF sera had stronger reactivity against mature Dsg1 plate than precursor Dsg1 plate. (d) Dispersion
of immunoreactivity of 20 mucocutaneous PV sera between the mature and precursor Dsg1 ELISA plate. Each closed triangle represents single patient. Similar to
PF patients, most PV sera had stronger reactivity against mature Dsg1 plate than against precursor Dsg1 plate.
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is dependent on the conformation of Dsg1 (Table 1), a
pathogenic anti-Dsg Ab has been described that binds a non-
conformational epitope (Yeh et al., 2006). In addition, it has
been reported that IgG against non-conformational epitopes
in pemphigus also correlated with clinical disease activity
(Muller et al. 2006, 2008). Although it remains to be
determined, it is not unreasonable to assume that the
prosequence could block the binding of pathogenic Abs
against both conformational and non-conformational patho-
logical epitopes.
High-resolution crystal structure analysis of the entire
extracellular domain of C-cadherin provided a mechanistic
basis for intermolecular cadherin interactions (Boggon et al.,
2002). The trans-adhesive interface is a two-fold symmetrical
interaction, as the conserved tryptophan (W2) side chain at
the amino-terminal end of the cadherin molecule from one
cell inserts into the hydrophobic pocket at the amino-
terminal end of a cadherin molecule on an opposing cell.
Recent cryo-electron tomography of vitreous sections from
human epidermis visualized the three-dimensional molecular
architecture of desmosomal cadherins, which resembled the
X-ray structure of C-cadherin (Al-Amoudi et al., 2007).
Considering the similarity of amino-acid sequences between
the ectodomains of classic cadherins and desmosomal
cadherins, they probably share similar adhesive domains.
Immunoblot analysis using domain-swapped molecule of
Dsg1/Dsg2 or Dsg3 revealed that the epitope of 3-30/3h was
mapped to amino acid 89–101 of the EC1 region of Dsg1
(Figure 5). When the amino-acid sequences of Dsg1 were
superimposed on the predicted structure of C-cadherin, the
predicted residues for the adhesive interface of the W2
acceptor sites (hydrophobic pocket) were 24I, 38Y, 78C,
80A, 89E, 91P, and 92L (Boggon et al., 2002). This putative
W2-acceptor sites partially overlapped with the presumed
epitope of 3-30/3h, indicating that the epitope of 3-30/3h is
located in a presumptive hydrophobic pocket of the adhesive
interface of Dsg1. Furthermore, previous studies suggested
that the prosequence of E-cadherin blocks the N-terminal
adhesive region of cadherin to prevent self-aggregation
during protein synthesis in the Golgi or endoplasmic
structure, and proteolytic processing creates the active form
by conformational changes or by exposure of active binding
sites (Ozawa and Kemler, 1990). In addition, the three-
dimensional structure study of the prosequence of N-
cadherin showed that the proregion is a structure similar to
the cadherin adhesive domain but lacking features for
cadherin–cadherin interactions, suggesting that the prose-
quence might render interaction sites less accessible and also
prevent the propagation of the interactions (Koch et al.,
2004). Therefore, by analogy, pathogenic Abs in pemphigus
sera target regions of Dsgs that are functionally important and
are unmasked by proteolytic processing. This finding is
consistent with the hypothesis that the direct inhibition of
trans-interaction of Dsg by autoantibodies plays a primary
role in inducing blister formation in the pemphigus. How-
ever, we cannot rule out an alternative hypothesis that Ab
binding to exposed adhesive sites in Dsg somehow causes
signaling inside the cells or internalization of Dsg, which
leads to acantholysis. In any case, our results showed the
importance of pemphigus Ab binding to Dsgs after adhesive
domains are exposed by its normal proteolytic processing
(Figure 9b).
We should mention that not all pathogenic autoantibodies
target the regions that are masked by the prosequence. For
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Figure 7. Majority of anti-desmoglein 3 (Dsg3) antibody binding in PV sera
targets the mature form more than the precursor form of Dsg1. (a)
Coomassie blue staining of purified recombinant baculoproteins used for
precursor and mature Dsg1 ELISA plates. White arrowhead indicates the
precursor form and black arrow head indicates the mature form. (b) Binding
curves of representative anti-Dsg3 mAbs (AK23, AK15) against mature and
precursor Dsg3 ELISA plates. (c) Dispersion of immunoreactivity of 47 PV sera
between the mature and precursor Dsg3 ELISA plates. Each closed square
represents single patient. Most PV sera showed stronger reactivity against
mature Dsg3 plate than against precursor Dsg3 plate.
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example, we have identified another weakly pathogenic anti-
Dsg1 monoclonal Ab (3-7/1e) that did not cause blisters in
mice, but induced slight blister formation in human skin (Ishii
et al., 2008). This Ab bound both the mature and the
precursor form of Dsg1. Epitope mapping using a domain-
swapped molecule of Dsg1/Dsg2 revealed that the epitope
resides in the EC2 domain of Dsg1 (data not shown). It may
be possible that such Abs block the cis-interaction of Dsgs.
The mechanism of blister formation by such Abs remains to
be determined.
Another major finding in this paper is that PF sera have a
subset of autoantibodies against only a precursor Dsg1.
The frequency of PF sera that contains Abs against the
precursor form of Dsg1 may be high because inhibition of
ELISA in a previous paper showed that the binding of the
non-pathogenic scFvs against precursor Dsg1 was inhibited
by four out of the six PF sera tested (Ishii et al., 2008).
However, in almost all PF sera, only a small proportion of
their reactivity is against the precursor form of Dsg1, as
shown by the competition ELISA of the PF sera by anti-Dsg1
scFvs (Figure 4), and by the finding that both PF and PV sera
have stronger reactivity against the mature than against the
precursor form of Dsg (Figures 6c and 7c). The epitope bound
by the scFv mAbs reacting exclusively against the precursor
form of Dsg1 could either be the prosequence itself or a
conformational epitope on Dsg1 stabilized by the prose-
quence and lost in the mature protein. Further definition of
this exact epitope awaits additional studies.
Cloned scFv that binds exclusively against the precursor
Dsg1 shows weak intracellular staining by indirect immuno-
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fluorescence, as opposed to the cell surface staining typical of
pemphigus. We think this staining is weak because there is
probably little intracellular precursor Dsg as most is
efficiently processed to the mature cell surface form. We
can detect this weak staining because we have potent
monoclonal scFv against precursor Dsg1, but such staining
would be difficult or impossible to appreciate with polyclonal
pemphigus sera that have a predominant Ab response against
the mature cell surface Dsg.
We do not know how these Abs against the precursor form
are involved in the pathogenesis in PF. It may be possible that
PF patients first develop Abs against the intracellular
precursor Dsg1, which may not normally be exposed to the
immune system but is released at times of keratinocyte injury,
and subsequently develop pathogenic Abs against mature
Dsg1. Another possibility is that Abs against the unprocessed
form of Dsg1 are developed after PF is active as a
consequence of the damage to keratinocytes.
The findings we presented here have clinical implications.
We showed that the disease activity was more precisely
correlated with the level of immunoreactivity against the
mature form of Dsg by ELISA than that against the premature
Dsg ELISA. There is another therapeutic implication of our
findings. We found that much of the immunoreactivity in
pemphigus sera target very restricted regions of Dsg that are
masked by the prosequece. Therefore, we could develop a
new therapeutic strategy by immunoadsorption of Abs against
such restricted regions.
In this study, we found that the majority of immunor-
eactivity in pemphigus sera targets the restricted regions that
are unmasked by proteolytic cleavage of prosequence. The
finer definition of the pathogenic hot spot on Dsg has
provided an important framework to understand the mole-
cular mechanism of blister formation in pemphigus, as well
as that of cell–cell adhesion in desmosomes.
MATERIALS AND METHODS
Human sera
Sera were obtained from 45 patients with PF and from 47 patients
with PV. The diagnosis of PF and PV was made on the basis of
clinical features, histology, and immunofluorescence findings. We
chose sera from the clinically active stage. For longitudinal follow-
up study, serum samples were collected from three PF and three PV
cases, which showed that the immunoreactivity against the mature
Dsg form was stronger than that against the precursor form and, as
unusual cases, from one PF and one PV case, which showed stronger
reactivity against the precursor form than against the mature form.
This study was approved by the institution review board of Keio
University and was conducted according to the Declaration of
Helsinki Principles. All samples were used with informed consent.
Production and purification of anti-Dsg1 scFv mAbs
We used four representative monoclonal anti-Dsg1 scFv Abs isolated
from a PF patient by phage display (Table 1). ScFv mAbs were
produced in the Top10F’ strain of E coli (Invitrogen, San Diego, CA)
and purified by Talon affinity resin (Clontech, Palo Alto, CA) as
previously described. (Ishii et al., 2008).
Production of AK series of mouse anti-Dsg3 mAbs
AK series of mouse AK7, AK15, and AK23 mAb against mouse and
human Dsg3 were prepared as previously described (Tsunoda et al.,
2003).
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Figure 9. Proteolytic processing of the precursor form of desmogleins (Dsgs)
and mAb binding to the precursor and mature form of Dsg1. (a) Dsgs are
thought to be synthesized as inactive precursor Dsgs with prosequences in the
endoplasmic reticulum. The prosequences are then removed by subtillisin-
like proprotein convertases before transporting them to the plasma membrane
and mature Dsgs are assembled into desmosomes. (b) Binding of anti-Dsg1
mAbs to the mature and the precursor form of Dsg1. The pathogenic mAb,
3-30/3h (shown in orange) binds to the mature Dsg1, but not the precursor
Dsg1. Some non-pathogenic mAbs, 3-97/1c and 3-94/O18O8 (shown in
green), bind to the precursor Dsg1. A non-pathogenic mAb, 1-18/L12 (shown
in blue), which recognizes the middle portion of Dsg1, binds to both mature
and precursor Dsg1. The pathogenic mAb bind the region of adhesive
interface of Dsg1, which are unmasked by proteolytic processing, perhaps
blocking trans-interaction of Dsgs.
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Plasmid constructs
Construction of pQE-Dsg1-facX. Plasmid pEVmod-Dsg1-EHis
with the entire extracellular domain of Dsg1 fused with E-tag and
his-tag has been described previously (Ishii et al., 1997). The
putative endoproteolytic cleavage site of Dsg1 (RQKR) was
substituted with the recognition site of blood coagulation factor Xa
(IEGR) using sequential PCR. In brief, the first step PCR was carried
out on pEVmod-Dsg1-EHis to generate two fragments (primers A and
B for fragment1, and primers C and D for fragment 2) with mutations
for the factor Xa recognition site at the 30end and 50end, respectively.
The two fragments encompassing the mutation were annealed with
each other and extended by mutually primed synthesis. Subse-
quently, this fragment was reamplified by a second PCR step using
primers A and D. The following are the primers used in this
sequential PCR: 50-primer A, 50-GAA-GAT-CTA-CCA-TGG-ACT-GGA-
GTT-TCT-TCA-G-30; 30-primer B, 50-CAT-TCA-CGG-CCT-TCG-ATT-
GAA-TGC-CAT-TTG-30; 50-primer C, 50-GAA-TCG-AAG-GCC-GTG-
AAT-GGA-TCA-AGT-TCG-30; 30-primer D, 50-CCG-GTC-GAC-ATG-
TAC-ATT-GTC-TGA-TAA-C. The final PCR product containing the
factor Xa recognition site was digested with an NcoI and SalI, and
ligated together with NcoI-XhoI-cut pQE-trisystem vector (Invitrogen).
This construct was designated as pQE-Dsg1-FacX (p330).
Production of recombinant baculoproteins
Precursor-FacX-Dsg1-EHis. pQE-Dsg1-FacX was cotransfected
with the Baculo-sapphire baculovirus DNA (Orbigen, San Diego, CA)
into cultured insect Sf9 cells, and recombinant viruses were obtained. For
baculoprotein production, High Five cells (Invitrogen) cultured in a
serum-free EX cell 405 medium (SAFC biosciences, Lenexa, KS) were
infected with high-titer virus stock and incubated at 271C for 3 days.
Precursor-FacX-Dsg1-EHis was secreted in the culture supernatant.
Mature-Dsg1-EHis. Dsg1-EHis baculoprotein was cleaved by
incubation with proprotein convertase furin (New England BioLabs,
Beverly, MA). Typically, 50 ml of the culture supernatant was
incubated with two units of furin at room temperature for 15 hours.
Production of highly purified mature and precursor ELISA plates
Highly purified precursor and mature Dsg1 plates. For
obtaining complete-precursor Dsg1-EHis, baculovirus-expressed
recombinant Dsg1-Ehis, which contained both the precursor and
the mature form, was purified by TALON affinity resin (Clontech)
and subsequently adsorbed by a 3-30/3h mAb beads column (Figure
4a) to eliminate the mature form of Dsg1-EHis. For obtaining
complete-mature Dsg1-EHis, recombinant Dsg1-EHis baculoprotein
was purified by TALON affinity resin, treated with furin
(20 unitmg1) for 16 hours at room temperature in the manufac-
turer’s recommended buffer (New England Biolabs), and subse-
quently passed through an affinity column containing 3-97/1C mAb
to absorb the precursor form (Figure 4a). The purified complete-
precursor Dsg1-EHis and complete-mature Dsg1-EHis were immo-
bilized on 96-well polystyrene plates (Maxisorb Immunoplate;
Nunc, Wiesbaden, Germany) by coating each well with 2.5 mgml1
of recombinant proteins at 41C for 20 hours.
Highly purified precursor and mature Dsg3 plates. For
obtaining complete-precursor Dsg3-EHis, baculovirus-expressed
recombinant Dsg3-Ehis, which contained both the precursor and
the mature form was purified by TALON affinity resin (Clontech) and
subsequently adsorbed by AK23 mAb-bound affinity column (Figure
4a) to eliminate the mature form of Dsg3-EHis (Figure 5a). For
obtaining complete-mature Dsg3-EHis, purified recombinant Dsg3-
EHis baculoprotein was treated with furin using the above protocol
and again purified on TALON affinity resin. Complete-precursor
Dsg3-EHis and complete-mature Dsg3-EHis were immobilized on
96-well polystyrene plates (Nunc).
For the longitudinal study to compare reactivity against mature
and precursor Dsg ELISA with disease activity, we measured OD of
pemphigus sera at an approximate dilution (1:100–1:6,400).
Dsg1 scFv ELISA
The reactivity of scFv against human Dsg1 was measured by Dsg1
ELISA (Medical and Biological Laboratories Co. Ltd, Nagoya, Japan)
using a horseradish peroxidase-conjugated anti-HA (Hemagglutinin)
monoclonal Ab (clone 3F10, 1:1,000 dilution, Roche Diagnostics
Corp., Basel, Switzerland) as a secondary Ab as described (Ishii
et al., 2008).
To increase the ratio of the mature form on a standard Dsg1 ELISA
plate, the plates were pretreated with 2U/ well of furin (New
England Biolabs, Ipswich, MA) in Tris-buffered saline with 1mM
CaCl2 at room temperature for 5 hours.
Indirect immunofluorescence
Immunofluorescence for scFvs was carried out on human skin as
previously described (Payne et al., 2005). Binding was detected using a
rat monoclonal anti-HA Ab (3F10, 1:100 dilution, Roche Diagnostics)
and thereafter using a Alexa Fluor 446-conjugated anti-rat IgG (1:200
dilution, Invitrogen). A confocal image was obtained using a Zeiss LSM
510 confocal microscope (Carl Zeiss Meditec, Dublin, CA).
Immunoblotting
The recombinant baculoproteins were size-fractionated by SDS-
PAGE and transferred to an Immobilon-P membrane (Millipore,
Bedford, MA), and detected using an anti-E-tag Ab (1:2,000 dilution,
GE Healthcare Bio-Sciences, Piscataway, NJ), followed by alkaline
phosphatase-conjugated goat anti-mouse IgG Abs (1:1,000 dilution,
DPRA-Zymax, San Francisco, CA).
Immunoprecipitation–immunoblotting analysis
Baculovirus-infected insect cell culture supernatants containing
recombinant proteins were incubated with anti-Dsg1 scFv mAbs
for 30minutes and then immunoprecipitated with anti-HA agarose
(Sigma-Aldrich, St Louis, MO) at 41C for 2 hours with gentle rotation.
After washing with Tris-buffered saline-calcium, the immunopreci-
pitates were resuspended in a Laemmli sample buffer, separated by
SDS-PAGE, and transferred to an Immobilon-P membrane (Milli-
pore). The membranes were probed with an anti-E-tag Ab (1:2,000
dilution, GE Healthcare Bio-Sciences) followed by alkaline phos-
phatase-conjugated goat anti-mouse IgG Abs (1:1,000 dilution,
DPRA-Zymax). The recombinant proteins used in the epitope
mapping of 3-30/3h mAb have been described previously
((Sekiguchi et al., 2001) and Chan et al. (manuscript in preparation)).
Inhibition ELISA
PF sera were diluted to result in an OD450 reading of B1.0 in the
Dsg1 ELISA without competitors. The diluted PF sera, mixed with
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scFv mAbs, were analyzed by standard Dsg1 ELISA (Medical and
Biological Laboratories) developed using a horseradish peroxidase-
conjugated anti-human Fab Ab. Inhibition was calculated according
to the following formula: % inhibition¼ (1(OD T/B–OD N/B)/(OD
T/BcOD N/Bc))*100, where T is the PF sera tested, N is the normal
control serum, B is the blocking monoclonal anti-Dsg1 scFvs, and Bc
is the control scFv.
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